PD-1 and PD-L1 Inhibitors Market | Key Competitors, Trends, Drivers and Challenges
AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Merck and Co. Inc., and Pfizer Inc. are among the key market vendors
Accelerating at a CAGR of 19.11%, the Global PD-1 and PD-L1 inhibitors market is expected to grow by $ 29.97 billion during the forecast period. Our research report offers growth projections of all the market segments, along with an in-depth analysis of all the factors that are likely to boost growth. This research also delves deep into issues that are likely to challenge market growth. This detailed analysis of the market will facilitate clients in planning a business strategy for the growth of their business in the post-pandemic era.
Request for Our Free Sample Report for detailed Insights
PD-1 and PD-L1 Inhibitors Market: Market Segments and Growth Forecasts
This research report will provide insights into the current market share of each segment along with growth projections for the next five years.
- Market is segmented by Application (solid tumors and blood-related tumors) and Geography (North America, Europe, Asia, and ROW). Growth by the solid tumors segment will be significant during the forecast period. The global PD-1 and PD-L1 inhibitors market has witnessed a significant increase in the drug approval for the treatment of various solid tumors during the last four years. This is owing to the high efficacy of PD-1 and PD-L1 inhibitors in blocking the cancer cells pathway and helping the T-cells to fight against the cancer-causing cells.
- 51% of the market growth will originate from North America during the forecast period. The US and Canada are the key markets for PD-1 and PD-L1 inhibitors in the region. However, the market growth rate in this region will be slower than the growth of the market in Asia which is a huge potential market.This report provides an accurate prediction of the contribution of all the geographic segments to the growth of the PD-1 and PD-L1 Inhibitors Market size.
PD-1 and PD-L1 Inhibitors Market: Trends, Drivers, Challenges
The report also offers a detailed impact analysis of various trends, drivers, and challenges that are likely to influence the market growth during the forecast period. These insights will equip clients to design a growth strategy for their business and area of operations.
- Reduction in cancer mortality rate will be a significant factor in driving the growth of the PD-1 and PD-L1 Inhibitors Market. PD-1 inhibitors and PD-L1 inhibitors are a group of anticancer drugs that block the activity of PD-1 and PDL1 immune checkpoint proteins present on the surface of cells. In a normal body PD-1 is bound to another protein called PD-L1, and it helps to keep T cells from killing other cells, including cancer cells. Therefore, immune checkpoint inhibitors, are used to block the activity of PD-1. This kind of immunotherapy is emerging as a front-line treatment for several types of cancer. Data across regions across the world indicates that developed regions where such therapies are available have been more successfult in reducing mortality rates arising from cancer as again regions where less developed countries where this therapy is not being used.
- Increasing prevalence of cancer will be instrumental in driving the market growth during the forecast period.
- Availability of alternative therapies such as targetted anti-cancer therapies, gene therapy and regenerative therapies will impact the growth of this market. However, proven efficacy of this therapy along with the large base of developing countries where cancer is a major cause of mortality will offer significant growth prospects for the market in focus.
PD-1 and PD-L1 Inhibitors Market: Vendor Analysis
- The market is fragmented.
- Agenus Inc., Amgen Inc., AnaptysBio Inc., AstraZeneca Plc, BeiGene Ltd., Bristol-Myers Squibb Co., Checkpoint Therapeutics Inc., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., and Pfizer Inc. are some of the major market participants.
- The unprecedented outbreak of COVID-19 in 2020 has had a significant impact on market segments had a ripple effect on various stakeholders. Our vendor analysis and insights will provide you with all the information required to make the most of the opportunities and plan business recovery and growth post the pandemic.
Key Areas Covered in our Report:
- PD-1 and PD-L1 Inhibitors Market Split by Application
- Solid tumors
- Blood-related tumors
- PD-1 and PD-L1 Inhibitors Market Split by Geography
- North America
- Europe
- Asia
- ROW
Customer landscape
Geographic Landscape
- Geographic segmentation
- Geographic comparison
- APAC - Market size and forecast 2020-2025
- MEA - Market size and forecast 2020-2025
- Europe - Market size and forecast 2020-2025
- North America - Market size and forecast 2020-2025
- South America - Market size and forecast 2020-2025
- Key leading countries
- Market opportunity by geography
- Market drivers
- Market challenges
- Market trends
Vendor Landscape
- Competitive scenario
- Vendor landscape
- Landscape disruption
Vendor Analysis
- Agenus Inc.
- Amgen Inc.
- AnaptysBio Inc.
- AstraZeneca Plc
- BeiGene Ltd.
- Bristol-Myers Squibb Co.
- Checkpoint Therapeutics Inc.
- F. Hoffmann-La Roche Ltd.
- Merck and Co. Inc.
- Pfizer Inc.
For more insights into this market: Download a Free Sample Report. Our custom reports provide market insights at the global and regional level along with pipeline analysis of new product launches. It also provides a peek into the latest R&D along with an impact analysis of government regulations.
The report provides insights into the following FAQs:
- What is the market CAGR?
The market will accelerate at a CAGR of 19.11%.
- What is the incremental growth of the market?
The market is expected to grow by $ 29.97 bn through 2021-2025.
- What is a key factor driving this market?
Reduction in cancer mortality rate will drive market growth over the forecast period.
- What are the key regions covered in this market research report?
North America, Europe, Asia, and ROW are the key regions featured in this research report.
- Which is the leading geographic region for this market:
51% growth will originate from North America
- Who are the leading market vendors?
The leading vendors in this market are Agenus Inc., Amgen Inc., AnaptysBio Inc., AstraZeneca Plc, BeiGene Ltd., Bristol-Myers Squibb Co., Checkpoint Therapeutics Inc., F. Hoffmann-La Roche Ltd., Merck and Co. Inc., and Pfizer Inc.
- What are the market segments covered in this report?
The market is segmented by Application (solid tumors and blood-related tumors) and Geography (North America, Europe, Asia, and ROW)
